TORONTO, Jan. 9, 2025
/PRNewswire/ - Apotex Inc. ("Apotex"), the largest Canadian-based
pharmaceutical company, today announced that its affiliate Nuvo
Pharmaceuticals (Ireland) DAC has
acquired the United States rights
to PROVIGIL (modafinil) and NUVIGIL (armodafinil). PROVIGIL and
NUVIGIL become the latest branded medicines to be sold in
the United States within the
Apotex Group's diversified global portfolio of more than 550
generic and branded prescription, over the counter and biosimilar
product families across all major therapeutic areas.
PROVIGIL and NUVIGIL each improve wakefulness in patients with
excessive sleepiness associated with narcolepsy, obstructive sleep
apnea or shift work sleep disorder, and are prescribed by
psychiatrists, endocrinologists, internists, sleep specialists, and
primary care physicians.
"Acquiring the US rights to PROVIGIL and NUVIGIL marks a
strategic milestone for Apotex and a significant initial step in
growing our US specialty business, building upon the recent
achievement of similar specialty transactions in Canada and advancing our Journey of Health
growth strategy," said Allan
Oberman, Apotex's President & CEO.
"These acquisitions further reinforce our long-term commitment
to improving patient care and continuing to expand our presence in
the US."
"PROVIGIL and NUVIGIL address critical needs for patients
experiencing excessive sleepiness. Leveraging our world-class
commercial team, established distribution networks, and expertise
in the US market, we are well-positioned to ensure these
medications continue to reach patients effectively," said
Christine Baeder, President of
Apotex Corp., Apotex's US affiliate.
About PROVIGIL and NUVIGIL
PROVIGIL and NUVIGIL are indicated to improve wakefulness in
adult patients with excessive sleepiness associated with
narcolepsy, obstructive sleep apnea (OSA), or shift work disorder.
More information on PROVIGIL is available here. More information on
NUVIGIL is available here.
About Apotex
Apotex is a Canadian-based global health company. We improve
everyday access to affordable, innovative medicines and health
products for millions of people around the world, with a broad
portfolio of generic, biosimilar, and innovative branded
pharmaceutical products. Headquartered in Toronto, with regional offices globally,
including in the United States,
Mexico, and India, we are the largest Canadian-based
pharmaceutical company and a health partner of choice for the
Americas for pharmaceutical licensing and product acquisitions.
Learn more about us at www.apotex.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/apotex-acquires-us-rights-to-provigil-modafinil-and-nuvigil-armodafinil-302347082.html
SOURCE Apotex Inc.
